Home Latest Articles
Latest Articles
  • Le KANG, Yan WANG, Qi FANG, Mudan HE
    World Clinical Drug. 2024, 45(10): 1091-1098.
    Objective

    To conduct a meta-analysis of the adverse drug reactions (ADR) caused by crizotinib in the treatment of anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC).

    Methods

    Literature on randomized controlled trials of crizotinib in the treatment of ALK-positive NSCLC published in domestic and foreign databases from the establishment of the database to August 2023 were searched. RevMan 5.4 software was used for meta-analysis.

    Results

    A total of 8 literatures were included, including 2 058 subjects (998 patients in crizotinib test group and 1 060 patients in chemotherapy or other targeted control group), and the quality of the included literatures was good. The overall incidence of ADR (≥grade 3) in test groups was lower than that in control group [RR=0.67, 95% confidence interval (CI): 0.46~0.96, P=0.03]. The incidence of leukopenia, neutrophils and thrombocytopenia (<grade 3) in test group was lower than that in other targeted groups (RR=0.71, 95%CI: 0.55~0.92, P=0.01). The incidence of upper respiratory tract infection (≥grade 3) and liver enzyme elevation (<grade 3) in test group was lower than that in chemotherapy group (RR=0.10, 95%CI: 0.01~0.95, P=0.04; RR=0.84, 95%CI: 0.74~0.94, P=0.004). The incidence of liver enzyme elevation in test group (≥grade 3) was higher than that in chemotherapy group (RR=2.13, 95%CI: 1.14~3.97, P=0.02).

    Conclusion

    Crizotinib has good overall safety and low blood system adverse reactions in the treatment of ALK-positive NSCLC. However, the liver function should be closely monitored to avoid the occurrence of adverse reactions of ≥grade 3 liver enzymes elevation.

  • Qing MA, Jianqi JIA, Qian HE
    World Clinical Drug. 2024, 45(10): 1099-1103.

    Semaglutide was approved by the U.S. Food and Drug Administration on March 8, 2024 for the prevention of cardiovascular disease, heart disease, and cerebral apoplexy in adults who are overweight or obese. Semaglutide improves blood glucose and traditional cardiovascular moderate risk factor levels in obese patients, reduces ectopic adipose tissue that can lead to atherosclerosis and myocardial dysfunction, and improves the systemic pro-inflammatory and pro-thrombotic environment associated with obesity. This article intended to elaborate the mechanism of action, clinical research and safety of semaglutide in the treatment of cardiovascular diseases complicated with obesity from multiple ways and levels, so as to provide certain reference for clinical use.

  • Gang ZHENG
    World Clinical Drug. 2024, 45(9): 903-906.

    At present, high-risk factors for cardiovascular disease such as hypertension and dyslipidemia have been effectively managed, but cardiovascular diseases remain the main cause of disability and mortality worldwide. Aging is an inevitable process in human life, and the cardiovascular system is no exception. Cardiovascular aging is closely related to an increased risk of cardiovascular diseases. Exploring the mechanisms of cardiovascular aging is of great significance for the treatment of cardiovascular diseases, drug development, and improvement of patient prognosis. This article reviewed the mechanism of cardiovascular aging, in order to provide reference for future research.

  • Gang ZHENG
    World Clinical Drug. 2024, 45(9): 907-913.

    The cardiovascular system operates under continuous mechanical and metabolic pressure, and as age increases, the risk of functional impairment at the molecular, cellular, and organ levels gradually increases. Especially with impaired macroautophagy function and epigenetic changes, including DNA methylation, histone modifications, and non-coding RNA. These cardiovascular aging mechanisms are closely intertwined, and the strengthening or weakening of individual mechanisms can affect other mechanisms. Understanding these cardiovascular aging mechanisms is expected to provide new ideas and directions for the diagnosis of cardiovascular diseases and the development of new drugs in the future.

  • Xuezhi WANG, Haitang WANG, Yujie XI
    World Clinical Drug. 2024, 45(9): 914-918.
    Objective

    To observe and compare the effects of Yuanhu Zhitong dropping pill and ibuprofen on pain and anxiety in patients with primary dysmenorrhea (PD).

    Methods

    Eighty patients with PD in the obstetrics and gynecology outpatient department of Shanggang community health service center from January to December 2023 were selected and randomly divided into the Yuanhu Zhitong dropping pill group and the ibuprofen group, with 40 patients in each group. The Yuanhu Zhitong dropping pill group was given oral administration of Yuanhu Zhitong dropping pill and the ibuprofen group was given oral ibuprofen for three consecutive days starting from the first day of menstruation for a total of five menstrual cycles. Visual analogue score (VAS), pain time and Hamilton anxiety scale were used to compare the pain and anxiety status of the two groups before, after treatment and the follow-up period.

    Results

    Compared with before treatment, the pain scores, pain duration and anxiety scores of patients in Yuanhu Zhitong dropping pill group and ibuprofen group significantly improved after treatment and during the follow-up period (P<0.001). The comparison between the two groups showed that after treatment and during follow-up, the pain score, pain duration, and anxiety score in the ibuprofen group were significantly lower than those in the Yuanhu Zhitong dropping pill group (P<0.001).

    Conclusion

    Both Yuanhu Zhitong dropping pill and ibuprofen can effectively reduce pain and improve anxiety in patients with PD, and ibuprofen is more effective than Yuanhu Zhitong dropping pill for pain episodes.

  • Shengnan ZHANG, Jinghua DENG, Yudong WANG
    World Clinical Drug. 2024, 45(9): 919-924.
    Objective

    To investigate the effects of Mashe Anjin pill combined with acetylcysteine nebulization inhalation therapy on sputum viscosity and oxygen metabolism in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

    Methods

    A total of 120 AECOPD patients admitted to our hospital from July 2021 to October 2023 were included and randomly divided into western medicine group and combination group by random number table method, with 60 cases in each group. The western medicine group was given acetylcysteine nebulization inhalation on the basis of conventional treatment, while the combination group was given oral administration of Mashe Anjin pill based on western medicine group. Both groups received continuous treatment for 14 days. The changes in sputum viscosity, blood gas analysis indexes [partial pressure of carbon dioxide (PaCO2), arterial oxygen pressure (PaO2) and oxygen saturation (SaO2)], pulmonary ventilation function indicators [forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and FEV1/FVC] in both groups were measured and recorded before and after treatment, and the clinical efficacy of each group was observed and compared.

    Results

    After treatment, the total effective rate of the western medicine group was lower than the combination group (75.00% vs 93.33%, P<0.05). The viscosity of sputum in both groups improved, and the improvement degree in the combination group was obviously better than that in the western medicine group (P<0.05). After treatment, the SaO2 and PaO2 in both groups were increased than before treatment (P<0.05), while the PaCO2 was decreased (P<0.05), and the SaO2 and PaO2 in the combination group were higher than the western medicine group (P<0.05), while the PaCO2 was lower than the western medicine group (P<0.05). After treatment, the FVC, FEV1, and FEV1/FVC of both groups were increased than before treatment (P<0.05), and the combination group were higher than the western medicine group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).

    Conclusion

    The combination of Mashe Anjin pill and acetylcysteine nebulization inhalation can effectively reduce sputum viscosity, improve oxygen metabolism and lung ventilation function, and improve clinical efficacy in AECOPD patients.

  • Xianhong HUO, Qitao GUO, Xiaohua SHI, Yali LIU, Zhixing ZHAO, Yuqiao YANG
    World Clinical Drug. 2024, 45(9): 925-930.
    Objective

    To investigate the curative effect of Shugan Hewei Jiangni decoction combined with herb-separated moxibustion on navel in the treatment of reflux esophagitis (RE) patients with liver and stomach dishonant syndrome.

    Methods

    A total of 112 cases of RE patients with liver and stomach disordered syndrome admitted to our hospital from September 2019 to September 2020 were selected and divided into control group (routine+herb-separated moxibustion on navel) and research group (routine+herb-separated moxibustion on navel+Shugan Hewei Jiangni decoction), with 56 cases in each group. The clinical efficacy, gastrointestinal hormone levels, gastrointestinal dynamics indexes, serum inflammatory factor levels before and after treatment and 6-month recurrence rate were compared between the two groups.

    Results

    After treatment, the total effective rate of the study group (94.64%) was higher than that of the control group (82.14%)(P=0.039). Compared with the control group, the levels of traditional Chinese medicine symptom score, serum cholecystokinin, vasoactive intestinal peptide, 5-hydroxytryptamine, C-reactive protein, tumor necrosis factor-α and interleukin-1β were significantly decreased in the study group (P<0.05), but the levels of gastrin, motilin and somatostatin were significantly increased (P<0.05). The 6 months recurrence rate of the study group (1.79%) was lower than that of the control group (16.07%)(P<0.05).

    Conclusion

    Shugan Hewei Jiangni decoction combined with herb-separated moxibustion on navel can effectively improve the clinical symptoms, regulate gastrointestinal hormone levels, improve gastric dynamics, regulate serum inflammatory factors and reduce the recurrence rate of patients with liver and stomach dishonant syndrome RE.

  • Huanhuan WANG, Erli GU
    World Clinical Drug. 2024, 45(9): 931-936.
    Objective

    To explore the effects of meropenem combined with probiotics on inflammatory response and intestinal mucosal barrier function in patients with spontaneous bacterial peritonitis (SBP) caused by liver cirrhosis.

    Methods

    A total of 102 patients with cirrhosis complicated with SBP who were treated in Jing-an district central hospital from January 2021 to March 2023 were selected as the study objects, and were divided into 52 cases in the control group (meropenem treatment) and 50 cases in the study group (meropenem combined with bifidobacterium triactive enteric capsule treatment). The curative effect, inflammatory factor levels, intestinal mucosal barrier function, and adverse reactions before and after the treatment were compared between the two groups.

    Results

    The total effective rate of the study group (94.00%) was significantly higher than that of the control group (78.85%)(P<0.05). After treatment, the levels of inflammatory factors, diamine oxidase, D-lactic acid and the ratio of urinary lactulose excretion rate to mannitol excretion rate were decreased in two groups (P<0.05), and the decrease was more significant in the study group than in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).

    Conclusion

    Probiotics combined with meropenem can effectively improve the clinical efficacy of cirrhosis complicated with SBP, inhibit the secretion of inflammatory factors, improve the intestinal mucosal barrier function of patients, and have a high safety.

  • Jun LI, Yanli YUE, Gaoqiang WANG, Hanyin LIU, Yuanfang ZHONG, Wei ZHANG
    World Clinical Drug. 2024, 45(9): 937-942.
    Objective

    To observe the effects of Yiqi Yangyin Qufeng recipe on inflammatory factors and oxidative stress in patients with type 2 diabetic nephropathy (DN).

    Methods

    A total of 60 patients with type 2 DN admitted to nephrology departments of outpatient and inpatient of our hospital from January 2022 to June 2023 were included and randomly divided into treatment group and control group, with 30 cases in each group. All patients were given lifestyle guidance to control blood glucose, blood lipids, etc. The treatment group was also given Yiqi Yangyin Qufeng recipe, and the control group was also given valsartan. The treatment course was 12 weeks. Traditional Chinese medicine (TCM) syndrome score, clinical efficacy, serum creatinine (Scr), urinary albumin/creatinine (UACR), peripheral blood mononuclear cell nuclear factor (NF)-κBP65, urinary monocyte chemotactic stimulating factor (UMCP)-1, interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-α, highly sensitive C-reactive protein (hs-CRP), superoxide dismutase (SOD), and serum malondialdehyde (MDA) levels were observed and compared between the two groups before and after treatment.

    Results

    The total effective rate of the treatment group was higher than that of the control group (86.67% vs 63.33%, P<0.05). The treatment group was superior to the control group in improving the levels of TCM syndrome score, UACR, NF-κBP65, TNF-α, IL-1, IL-6, SOD, MDA and UMCP-1 (P<0.05), and there were no significant differences in the levels of Scr and hs-CRP between the two groups (P>0.05). Correlation analysis showed that NF-κBp65 was positively correlated with UMCP-1 (r=0.562 1, P<0.05).

    Conclusion

    Yiqi Yangyin Qufeng recipe can reduce the expression level of inflammatory factors and inhibit oxidative stress in type 2 DN patients, which can be regarded as one of the effective drugs for type 2 DN.

  • Yuxin SHEN, Qiannan ZHANG, Hong XIA, Yingji YU, Junhui LI
    World Clinical Drug. 2024, 45(9): 943-949.
    Objective

    To explore the correlation between blood magnesium level in patients with maintenance hemodialysis (MHD) and cardiovascular events and all-cause death.

    Methods

    The clinical data of 122 patients treated with MHD in our hospital from January 2021 to January 2023 were retrospectively analyzed, and the patients were divided into high magnesium group (blood magnesium≥0.93 mmol/L, n=67) and low magnesium group (blood magnesium<0.93 mmol/L, n=55) according to the median blood magnesium level. Kaplan-Meier survival curve was used to compare the cumulative survival rate of the two groups, and Cox regression model was used to analyze the risk factors of all-cause death.

    Results

    The levels of serum albumin, prealbumin, magnesium, phosphorus and C-reactive protein were significantly different between the two groups (P<0.05). The incidence of cardiovascular events and all-cause mortality in low magnesium group were higher than those in high magnesium group (P<0.05). The cumulative survival rate of low magnesium group was significantly lower than that of high magnesium group (P<0.01). Univariate Cox regression analysis showed that hypomagnesium was a risk factor for cardiovascular events and all-cause death (P<0.01). After multifactor correction, hypomagnesium was an independent risk factor for cardiovascular events, but not an independent risk factor for all-cause death (P>0.05).

    Conclusion

    MHD patients with low blood magnesium levels have a higher incidence of cardiovascular events and an increased risk of all-cause death.

News